ClinicalTrials.gg
CompletedNCT07144111Updated Oct 23, 2026

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

A Phase 1 interventional study of Inavolisib in Hepatic Impairment, sponsored by Genentech, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Updated Oct 23, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This open-label study will evaluate the effect on the pharmacokinetics (PK), safety, and tolerability of a single oral dose of inavolisib in participants with moderate or severe hepatic impairment compared with demographically matched healthy participants with normal hepatic function.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants:

  • 18.0 to 40.0 kilogram per meter square (kg/m\^2), inclusive, and body weight >=45 kg.
  • Negative surface antigen (HBsAg) test
  • Positive hepatitis B surface antibody (HBsAb) test or negative HBsAb
  • Negative (Human Immunodeficiency Virus) test
  • Females will not be pregnant or breastfeeding and must be either or surgically sterile
  • Males will agree to use and will refrain from sperm donation

Healthy participants (Cohort 1):

  • Negative virus (HCV) antibody test or positive HCV antibody test followed by a negative HCV RNA test
  • Normal hepatic function and no history of hepatic dysfunction

Participants with Hepatic Impairment (Cohorts 2 and 3):

  • Considered to have moderate ( score of 7 to 9) or severe (Child-Pugh score of 10 to 15) hepatic impairment
  • Chronic, stable hepatic insufficiency with features of cirrhosis
  • Negative hepatitis C viral load

Exclusion criteria

Exclusion Criteria:

All participants:

  • History of Type 1 diabetes or Type 2 Diabetes that is insulin-dependent or requires ongoing systemic treatment with two or more agents
  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder
  • Significant illness, surgery, or hospitalization within 2 weeks prior to dosing.
  • History of gastro-intestinal surgery
  • Malabsorption syndrome or any other condition that would interfere with enteral absorption.
  • History of active or latent Mycobacterium tuberculosis (TB), regardless of treatment history, or positive QuantiFERON® TB Gold test
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance
  • Use of drugs of abuse (including opioids)

Healthy participants (Cohort 1):

- History of alcoholism or drug addiction

Participants with Hepatic Impairment (Cohorts 2 and 3):

  • Hepatic impairment due to hepatocellular carcinoma or bile duct cancer
  • Surgical or artificial portosystemic shunt (e.g., transjugular intrahepatic portosystemic shunt)
  • Evidence of hepatorenal syndrome
  • Ascites requiring paracentesis
  • Any evidence of progressive liver disease in the last 1 month
  • Receipt of a liver transplant
  • Hepatic encephalopathy Grade 2 or above
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants with normal hepatic function will receive a single oral dose of inavolisib on Day 1

    Drug: Inavolisib

  • Experimental
    Cohort 2

    Participants with moderate hepatic function will receive a single oral dose of inavolisib on Day 1

    Drug: Inavolisib

  • Experimental
    Cohort 3

    Participants with severe hepatic function will receive a single oral dose of inavolisib on Day 1

    Drug: Inavolisib

Interventions

  • Participants will receive a single oral dose of inavolisib

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Inavolisib

    Time frame: Pre-dose (0 hour), 30 minutes (min), 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72, and 96 hours postdose

  2. Area Under Curve (AUC) from Hour 0 to the Last Measurable Concentration (AUC [0-t]) of Inavolisib

    Time frame: Pre-dose (0 hour), 30 minutes (min), 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72, and 96 hours postdose

  3. AUC from Zero to Infinity (AUC [0-inf]) Extrapolated of Inavolisib

    Time frame: Pre-dose (0 hour), 30 minutes (min), 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72, and 96 hours postdose

  4. Geometric Mean Ratio of Cmax of Inavolisib

    Time frame: Pre-dose (0 hour), 30 minutes (min), 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72, and 96 hours postdose

  5. Geometric Mean Ratio of AUC (0-t) of Inavolisib

    Time frame: Pre-dose (0 hour), 30 minutes (min), 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72, and 96 hours postdose

  6. Geometric Mean Ratio of AUC (0-inf) of Inavolisib

    Time frame: Pre-dose (0 hour), 30 minutes (min), 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72, and 96 hours postdose

Secondary outcomes

  1. Percentage of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: From Baseline up to Follow-up (Day 8)

07

Study locations

4 sites
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809-3017, United States
  • The Texas Liver Institute, Inc.
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research - San Antonio
    San Antonio, Texas 78229, United States
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2025 to primary completion in Oct 2026, 13 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Nov 2026 → Oct 2026 and completion Nov 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Aug 27, 2025
StartActual
Aug 21, 2025
Primary completionActual
Oct 13, 2026was Nov 2026
CompletionActual
Oct 13, 2026was Nov 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 23, 2026
Primary completion
Nov 16, 2026→Oct 13, 2026 (actual)
Oct 23, 2026
Study completion
Nov 16, 2026→Oct 13, 2026 (actual)
Oct 23, 2026
Enrollment
32 (estimated)→27 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Completed
    Primary completion Nov 16, 2026→Oct 13, 2026 (now actual)
    Study completion Nov 16, 2026→Oct 13, 2026 (now actual)
    Enrollment 32 (estimated)→27 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07144111
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Aug 21, 2025
Primary completion
Oct 13, 2026
Completion
Oct 13, 2026
Last update
Oct 23, 2026

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inavolisib

Start the discussion